TrialImmunotherapy2025

Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.

Tomoko Hasunuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.